P76.12 Impact of Inflammatory Markers and Body Mass Index on TKI Toxicity in Patients With Non-Small Cell Lung Cancer Harboring an EGFR Mutation

Abstract

Among these patients, 35 (58.3%) patients were female. And 14 (23.3%) of them had brain metastasis. Till August 2020, 57 of the patients received at least once tumor assessment. 51 of them achieved partial response, 6 of them had stable disease and no patients had disease progression. The ORR was 89.5%, while the DCR was 100 %. The most common grade 3 adverse event (AE) are rash (15.3 %), oral mucositis (10.2%) and diarrhea (8.5 %). A grade 4 hypertension were observed. Conclusion: This is the first study of the new combination of anlotinib plus erlotinib. The results suggest that this strategy could be a new first-line therapy in EGFRmutated NSCLC patients. The long-term outcomes will be revealed in the future.